The Pressures Are Obvious, But Our Stocks Are Better Than Most
Commodity prices continued their exponential rise this week, as the conflict in the Ukraine has escalated. The latest example of truly outrageous prices was the
Not Out of the Woods Yet
After a painful January, bargain hunters are starting to return and dip their toes back into the stock market. Many stocks are now well off
The Value Rally In Perspective
While many investors are finding the start of 2022 painful, Value Authority subscribers are already doing well following a strong 2021. Higher interest rates and
The Rally Is Back! But For How Long?
The rally is back. It did not take long for the Russell 3000 Value Index (IUSV) to rebound to just within sight of its all-time
We’re In The Sweet Spot
The Russell 3000 Value Index (IUSV) is trading at all-time highs following a typical September crisis of confidence followed by a strong October. While earnings
Earnings Will Provide Clarity, Which Is All We Need
Sometimes it feels like the only thing holding cautious optimists back is the irrational dread of other investors. But while their moods can temporarily weigh
A Turn Is In The Air
We are nothing if not patient, waiting weeks and months for the moment when the market mood turns explosively in our favor . . .
Patience Will Be Rewarded
Despite a very strong earnings season, the Russell 3000 Value Index remains slightly below its May peak as the market struggles with concerns over how
Our Turn Will Come
Value stocks, which have underperformed the market since the middle of May, have been trying to rally over the last few weeks. The reasons for
The Rally Goes On
The great reset in value stocks that got underway when COVID vaccines proved to be effective in clinical trials has probably run its course. After
Are We Seeing Too Much of a Good Thing?
Until yesterday afternoon, there was seemingly a non-stop rush by investors to sell every tech stock and then reinvest the funds in a financial or
Gains Have Been Huge, What is the Next Step?
It has been a little over five months since encouraging news about COVID-19 vaccine data came out, which launched a huge rally in dormant value